Ames, F.R. and Cridland S. 1986. Anticonvulsant effect of cannabidiol. S.Afr.Med.J. 69: 14
Consroe, P.F. et al. 1975. Anticonvulsant nature of marijuana smoking. J.A.M.A. 234: 306 - 307.
Cunha, J.M. et al. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175 - 185.
Davis, J.P. and Ramsey, H.H., 1949. Anti-epileptic action of marijuana-active substances. Fed. Proc. Am. Soc. Exp. Biol. 8: 284
Feeney, R. and Turkanis, S.A. 1981. The cannabinoids as potential antiepileptics. J.Clinical Pharmacology 21: 437S - 448S.
Karler, R. et al., 1973. The anticonvulsant activity of cannabibidol and cannabinol. Life Sci. 13: 1527 - 1531
Karler, R. et al. 1984. Interaction between delta-9-tertrahydrocannabinol and kindling by electrical and chemical stimulation in mice. Neuropharmacology 23: 1315 - 1320
Karler, R. et al., 1989. Pentylenetetrazole kindling in mice. delta-9-tertrahydrocannabinol 28: 775 - 780
Karler, R. et al., 1974. Anticonvulsant properties of delta-9-tertrahydrocannabinol and other cannabinoids. Life Sci. 15: 931 - 947
Karler, R. et al., 1986. Prolonged hyperexcitability in mice after a single exposure to delta-9-tertrahydrocannabinol. Neuropharmacology 25: 441 - 446
Karler, R. and Turkanis, S. 1976. The anti-epileptic potential of the cannabinoids. In the Therapeutic Potentail of Marijuana, Cohen and Stillman, Eds., Plenum Press, New York, pp 383 - 396
Turkanis, S. et al. 1974. Anti-convulsant properties of cannabinol. Res. Comm. Chem. Patol. Pharmacol. 8 : 231 - 246
Consroe P. et al., 1986. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30: 277 - 282
Consroe P. et al., 1991. Controlled clinical trial of cannabidiol in Huntington's Disease. Pharmacol. Biochem. Behav. 40: 701 - 708
Frankel, J.P. et al. 1990 Marijuana for Parkinsonian tremor. J. Neurol, Neurosurg. Psychiatry 53 : 436
Hemming M. and Yellowie, P.M. 1993. Effective treatment of Tourette's-Syndrome with marijuana. J. Psuychopharmacol. 7: 389 - 391.
Moss D.E. et al., 1989. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci. 44: 1521 - 1525
Sandyk, R. et al., 1986. Cannabidiol in dystonic movement disorders. Psychiatry Res. 18 : 291 Snider, S.R. and Consroe, P. 1984. Treatment of Meige syndrome with cannabidiol. Neorology 34(S1): 147
Snider, S.R. and Consroe,P. 1985. Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induces dystonic dyskinsia. Neurology 35(S1): 201
Clifford, David B., 1983. Tetrahydrocannabinol for tremor in Multiple Scerosis. Ann. Neurol. 13: 669 - 671
Dunn, M. and Davis, R. 1974. The percieved effects of marijuana on spinal cord injured males. Paraplegia 12: 175.
Elkin.R., et al., 1987. Delta-9-tertrahydrocannabinol: a novel treatment of inflammatory demyelination. Fed. Proc. 46: 1378
Greenberg, H.S. et al., 1990. Marijuana nd its efefcts on postural stability in Multiple Sclerosis patients with controls. Neurology 40(S1): 259.
Hanigan, W.C. et al., 1986. The effects of delta-9-tertrahydrocannabinol on human spasticity. J.Am.Soc.Clin.Pharmacol. 39 : 198
Lyman, W.D. et al., 1989. Delta-9-tertrahydrocannabinol: A novel treatment for experimental autoimmune encephalitis. J. Neuroimmunol 23: 73 - 82
Malec, J. et al., 1982. Cannabis effect on spasticity in spinal cord injury. Arch.Phys.Med.Rehab. 63: 116
Mauer, M. et al., 1989. Delta-9-tertrahydrocannabinol shows anti-spasticity and analgesic effects in single case double-blind trial. Eur.Sarch.Psychiatry Clin.Neorosci. 240: 1 - 4
Meinck, H.M. et al., 1989. Effect of cannabinoids on spasticity and ataxia in Multiple Sclerosis. J. Neurol. 236: 120 - 122
Petro, D. 1980. Marijuana as therapeutic aagent for muscle spasm or spasticity. Psychosomatics 21: 91 - 85
Petro, D. and Ellenberger, C. Jr., 1981. Treatment of human spasticity with delta-9-tertrahydrocannabinol. J.Clin.Pharmacol. 21: 413S --416S
Truong, X.T. and Hanigan, W.C. 1986. Effect of delta-9-tertrahydrocannabinol on electromyographic measurements in human spasticity. J.Am.Soc.Clin.Pharmacol.Therap. 39: 232
Ungerleider, J.T. et al., 1987. Delta-9-tertrahydrocannabinol in the treatment of spasticity associated with Multiple Sclerosis. Adv.Alcohol Subst.Abuse 7: 39-50
UK: Rheumatoid Arthritis Treatment From Cannabis: BBC News (UK Web), 1 August 2000
Harris,L., 1976. Analgesic and antitumor poential of the cannabinoids. In the Theraputic Potentail of Marijuana, Cohen and Stillman, Eds, Plenum Press, New Yprk, pp 299 - 305
Milstein, S.L. et al., 1975. Marijuana-produced changes in pain tolerance: experienced and non-experienced subjects. Int.Pharmacopsychiatry 10: 177 - 182.
Noyes, S.J. Jr. and Baram, D.A., 1974. Cannabis analgesia. Compr. Psychiatry 15: 5
Noyes, S.J. Jr. et al., 1975. The analgesic properties of delta-9-tertrahydrocannabinol and codeine. Clin.Pharmacol.Ther. 18: 84 - 89
Noyes, S.J. Jr. et al., 1975. The analgesic effect of delta-9-tertrahydrocannabinol and codeine. J.Clin.Pharmacol.. 15: 139
Volfe,Z. et al., 1985. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int.J.Clin.Pharm.Res. 5: 243 - 246
Zeidenberg, P. et al., 1973. Effect of oral administration of delta-9-tertrahydrocannabinol on memory, speech and perception of thermal stimu;lation: results with four normal human subjects. Prelim. Report. Compr.Psychiatry 14 : 549
Bateman, D.N., 1987. Delta-9-tertrahydrocannabinol and gastric emptying. Br.J.Clin.Pharmacol. 15 : 139
Douthwaite, A.H., 1947. Choice of drugs in the treatment of duodenal ulcer. Br.Med.J. 43 : 4514
Nalin, D.R. et al., 1978. Cannabis, hypochlorhydria and cholera. Lancet 2 : 859
Sofia, R.D. et al., 1978. Evaluation of antiulcer activity of delta-9-tertrahydrocannabinol in the Shay rat test. Pharmacology 17: 173